natgillin/translations-raw huggingface dataset:
A crystalline Nilotinib HCl, characterized by data selected from the group consisting of: an x-ray powder diffraction pattern having peaks at 5.7, 9.8, 15.0, 15.8 and 17.3 degrees two theta ± 0.2 degrees two theta; a solid-state 13C NMR spectrum with signals at 113.1, 133.1, 160.9 ± 0.2 ppm; a solid-state 13C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 9.2, 29.2 and 57.0 ±0.1 ppm, wherein the signal exhibiting the lowest chemical shift in the chemical shift area of 100 to 180 ppm is at 103.9 ± 1ppm; and combinations thereof. 
Kristalni Nilotinib HCl, naznačen time da su podaci odabrani iz skupine koja sadrži: uzorak rendgenske difrakcije praha koji ima vrške kod 5.7, 9.8, 15.0, 15.8 i 17.3 stupnjeva dva theta ± 0.2 stupnjeva dva theta; 13C NMR spektar čvrstog stanja sa signalima kod 113.1, 133.1, 160.9 ± 0.2 ppm; 13C NMR spektar čvrstog stanja koji ima razlike kemijskih pomaka između signala koji iskazuje najniži kemijski pomak i drugog u rasponu kemijskog pomaka od 100 do 180 ppm od 9.2, 29.2 i 57.0 ± 0.1 ppm, pri čemu signal koji iskazuje najniži kemijski pomak u području kemijskog pomaka od 100 do 180 ppm je na 103.9 ± 1 ppm; te njihove kombinacije.
The crystalline Nilotinib HCl of claim 1, characterized by an x-ray powder diffraction pattern having peaks at 5.7, 9.8, 15.0, 15.8 and 17.3 degrees two theta ± 0.2 degrees two theta. 
Kristalni Nilotinib HCl prema zahtjevu 1, naznačen time da uzorak rendgenske difrakcije praha ima vrške kod 5.7, 9.8, 15.0, 15.8 i 17.3 stupnjeva dva theta ± 0.2 stupnjeva dva theta.
The crystalline Nilotinib HCl of claim 1, characterized by a solid-state 13C NMR spectrum with signals at 113.1, 133.1, 160.9 ± 0.2 ppm. 
Kristalni Nilotinib HCl prema zahtjevu 1, naznačen time da ima 13C NMR spektar čvrstog stanja sa signalima kod 113.1, 133.1, 160.9 ±0.2 ppm.
The crystalline Nilotinib HCl of claim 1, characterized by a solid-state 13C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 9.2, 29.2 and 57.0 ± 0.1 ppm, wherein the signal exhibiting the lowest chemical shift in the chemical shift area of 100 to 180 ppm is at 103.9 ± 1ppm. 
Kristalni Nilotinib HCl prema zahtjevu 1, naznačen time da 13C NMR spektar čvrstog stanja ima razlike kemijskih pomaka između signala koji iskazuje najniži kemijski pomak i drugog u rasponu kemijskog pomaka od 100 do 180 ppm od 9.2, 29.2 i 57.0 ±0.1 ppm, pri čemu signal koji iskazuje najniži kemijski pomak u području kemijskog pomaka od 100 do 180 ppm je na 103.9 ± 1 ppm.
The crystalline Nilotinib HCl of claim 2, further characterized by x-ray powder diffraction pattern having peaks at 7.6, 11.4, 18.7, 19.7 and 20.7 degrees two theta ± 0.2 degrees two theta. 
Kristalni Nilotinib HCl prema zahtjevu 2, dodatno naznačen time da uzorak rendgenske difrakcije praha ima vrške kod 7.6, 11.4, 18.7, 19.7 i 20.7 stupnjeva dva theta ± 0.2 stupnjeva dva theta.
The crystalline Nilotinib HCl of claim 8, having less than 10% w/w of Nilotinib HCl form A, wherein form A is characterized by an x-ray powder diffraction pattern having at least two maxima selected from 8.5, 11.0, 11.5, 17.2, 18.8, 19.2, 20.8, 22.1 and 26.0 degrees two theta ±0.2 degrees two theta. 
Kristalni Nilotinib HCl prema zahtjevu 8, koji ima manje od 10% tež/tež. Nilotinib HCl oblika A, pri čemu oblik A je naznačen time da uzorak rendgenske difrakcije praha ima barem dva maksimuma odabrana od 8.5, 11.0, 11.5, 17.2, 18.8, 19.2, 20.8, 22.1 i 26.0 stupnjeva dva theta ±0.2 stupnjeva dva theta.
The crystalline Nilotinib HCl of claim 8, having less than 10% w/w ofNilotinib HCl form A, wherein form A is characterized by an x-ray powder diffraction pattern having at least four maxima selected from 8.5, 11.0, 11.5, 17.2, 18.8, 19.2, 20.8, 22.1 and 26.0 degrees two theta ± 0.2 degrees two theta. 
Kristalni Nilotinib HCl prema zahtjevu 8, koji ima manje od 10% tež/tež. Nilotinib HCl oblika A, pri čemu oblik A je naznačen time da uzorak rendgenske difrakcije praha ima barem četiri maksimuma odabrana od 8.5, 11.0, 11.5, 17.2, 18.8, 19.2, 20.8, 22.1 i 26.0 stupnjeva dva theta ±0.2 stupnjeva dva theta.
The crystalline Nilotinib HCl of claim 8, having less than 10% w/w of Nilotinib HCl form A, wherein form A is characterized by an x-ray powder diffraction pattern having all maxima selected from 8.5, 11.0, 11.5, 17.2, 18.8, 19.2, 20.8, 22.1 and 26.0 degrees two theta ± 0.2 degrees two theta. 
Kristalni Nilotinib HCl prema zahtjevu 8, koji ima manje od 10% tež/tež. Nilotinib HCl oblika A, pri čemu oblik A je naznačen time da uzorak rendgenske difrakcije praha ima sve maksimume odabrane od 8.5, 11.0, 11.5, 17.2, 18.8, 19.2, 20.8, 22.1 i 26.0 stupnjeva dva theta ± 0.2 stupnjeva dva theta.
or and R2 are linked to one another and form a carbon ring containing 5 or 6 carbon atoms, with the carbon atom to which they are attached, and R3 and R4, which may be identical or different, represent: 
hidroksil, ili i R2 su spojeni zajedno i sa atomom ugljika na koji su spojeni tvore ugljikov prsten koji sadrži 5 ili 6 ugljikovih atoma, te R3 i R4, koji mogu biti isti ili različiti, predstavljaju:
a C1-C4 alkyl radical, X represents an oxygen atom or a sulphur atom, Y represents a hydrogen, a chlorine atom or a fluorine atom, m can have the value 1 or 2 and n can have the value 0 or 1, and when n = 0, then m = 1 or 2, and when n = 1, then m = 1, and also the salts of the compounds of general formula (I), and the isomer forms which are the cis and trans forms relative to the substituents on the heterocycloalkyl at position 4 of the benzene-1,3-diol, and enantiomer forms thereof. 
vodik, radikal C1-C4 alkila, X predstavlja atom kisika ili atom sumpora, Y predstavlja vodik, atom klora ili atom fluora, m može imati vrijednost 1 ili 2 i n može imati vrijednost 0 ili 1, i kada n = 0, tada m = 1 ili 2, i kada n = 1, tada m = 1, i također soli spojeva opće formule (I), te izomerni oblici koji su cis i trans oblici u odnosu na supstituente na heterocikloalkilu u položaju 4 na benzen-1,3-diolu, te njihovi enantiomerni oblici.
Compound according to Claim 1, characterized in that it is in the form of a salt formed with a base chosen from organic bases and inorganic bases. 
Spoj prema zahtjevu 1, naznačen time da je u obliku soli baze koja je odabrana od organskih baza i anorganskih baza.
Compound according to Claim 1 or 2, characterized in that it is in the form of a hydrate or of a solvate. 
Spoj prema zahtjevu 1 ili 2, naznačen time da je u obliku hidrata ili solvata.
represents a hydrogen, a C1-C4 alkyl radical or a hydroxymethyl radical, 
predstavlja vodik, radikal C1-C4 alkila ili radikal hidroksimetila, predstavlja vodik,
X represents an oxygen atom, 
X predstavlja atom kisika,
Y represents a hydrogen or a fluorine atom, 
Y predstavlja vodik ili atom fluora,
Compound according to one of Claims 1 to 4, characterized in that it is chosen from the group constituted of: 
Spoj prema jednom od zahtjeva 1 do 4, naznačen time da je odabran iz skupine koja sadrži:
Use according to Claim 6, for the treatment and/or prevention of pigmentary disorders. 
Uporaba prema zahtjevu 6, naznačena time da je za liječenje i/ili sprečavanje pigmentacijskih poremećaja.
Use according to Claim 7, characterized in that the pigmentary disorders are chosen from melasma, chloasma, lentigines, senile lentigo, irregular hyperpigmentations related to photoageing, freckles, post-inflammatory hyperpigmentations due to an abrasion, a burn, a scar, dermatosis, a contact allergy; naevi, genetically determined hyperpigmentations, hyperpigmentations of metabolic or drug-related origin, melanomas or any other hyperpigmentary lesion. 
Uporaba prema zahtjevu 7, naznačena time da su pigmentacijski poremećaji odabrani od melasma, kloasma, lentigines, staračkog lentiga, nepravilnih hiperpigmentacija povezanih sa fotostarenjem, pjegavost, post-upalne hiperpigmentacije zbog abrazije, opekotine, ožiljka, dermatoze, kontaktne alergije; madeža, genetskih hiperpigmentacija, hiperpigmentacija metaboličkog porijekla ili porijekla povezanog za lijekovima, melanoma ili bilo kojih drugih hiperpigmentacijskih lezija.
Cosmetic use of a composition comprising at least one compound according to one of Claims 1 to 5, for protecting against the harmful aspects of the sun, for preventing and/or combating photoinduced or chronological ageing of the skin and skin appendages, and for body or hair hygiene. 
Kozmetička uporaba pripravka koji sadrži barem jedan spoj prema jednom od zahtjeva 1 do 5, naznačena time da je za zaštitu protiv štetnih utjecaja sunca, za sprečavanje i/ili suzbijanje fotoinduciranog ili kronološkog starenja kože i naboranosti kože, te za higijenu tijela ili kose.
A salt according to claim 1 selected from the group consisting of: 
Prema zahtjevu 1, sol odabrana iz skupine koja se sastoji od:
A pharmaceutical composition comprising a therapeutically effective amount of a salt according to any one of claims 1 or 2 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži terapeutski učinkovitu količinu soli u skladu sa zahtjevom 1 ili 2 i farmaceutski prihvatljiv nosač.
A combination comprising a salt as defined in any one of claims 1 or 2 and one or more other therapeutic agent, as defined in any one of claims 5 to 10. 
Kombinacija koja se sastoji od soli kao što je definirano u zahtjevu 1 ili 2 ijedan ili više terapijskih agenata kao što je definirano u bilo kojem od zahtjeva od 5 do 10.
A salt according to any one of claim 1 or 2, a pharmaceutical composition according to any one of claims 3 to 10 or a combination according to claim 11, for use in the treatment of a pathological condition or disease associated with β2 adrenergic receptor activity. 
Sol kao što je definirano zahtjevom 1 ili 2, farmaceutski pripravak u skladu s bilo kojim od zahtjeva od 3 do 10 ili kombinacija prema zahtjevu 11, za upotrebu u liječenju patoloških stanja ili bolesti povezanih s aktivnošću beta2-adrenergičkihreceptora.
to 20 wt.% phospholipids based on total lipids or ii) 0.6 to 25 wt.% of polar lipids based on total lipids, wherein polar lipids are the sum of phospholipids, glycosphingolipids and cholesterol, and said composition comprising lipid globules with a core comprising said vegetable lipids and a coating comprising said phospholipids or polar lipids, for use in improving body composition, the improvement of body composition being selected from the group consisting of increased lean body mass, decreased fat mass, and decreased fat mass relative to total body weight. 
0,5 do 20%, težinski, fosfolipida na osnovu ukupnih lipida ili ii) 0,6 do 25%, težinski, polarnih lipida na osnovu ukupnih lipida, gdje su polarni lipidi zbir fosfolipida, glikosfingolipida i kolesterola, gdje navedeni pripravak sadrži lipidne globule, čiju jezgru čine navedeni biljni lipidi, a oblogu čine navedeni fosfolipidi ili polarni lipidi, namijenjen upotrebi u poboljšavanju tjelesnog sastava, gdje se poboljšavanje tjelesnog sastava bira iz skupine koju čine povećana nemasna tjelesna masa, smanjena masa masnog tkiva, te smanjena masa masnog tkiva u odnosu na ukupnu tjelesnu težinu.
to 25 wt.% of polar lipids based on total lipids, wherein polar lipids are the sum of phospholipids, glycosphingolipids and cholesterol based on total lipids and said composition comprising lipid globules with a core comprising said vegetable lipids and a coating comprising said polar lipids, wherein said lipid globules have 
0,6 do 25%, težinski, polarnih lipida na osnovu ukupnih lipida, gdje su polarni lipidi zbir fosfolipida, glikosfingolipida i kolesterola na osnovu ukupnih lipida, gdje navedeni pripravak sadrži lipidne globule, čiju jezgru čine navedeni biljni lipidi, a oblogu čine navedeni polarni lipidi, gdje navedene lipidne globule imaju
Package according to anyone of claims 1 to 17, characterised in that the package (1; 80; 90; 100; 110; 130; 150; 180) contains tobacco-related articles, wherein the tobacco-related articles are selected from the following group: cigarettes, cigarillos, cigars, tobacco-containing rods, smokeless tobacco, simulated smoking devices, inhalors without combustion of tobacco, aroma reservoirs. 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time što omot za pakiranje (1; 80; 90; 100; 110; 130; 150; 180) sadržava proizvode koji su vezani uz duhan, pri čemu su proizvodi koji su vezani uz duhan odabrani iz sljedećih skupina: cigarete, cigarilosi, cigare, šipke koje sadržavaju duhan, duhan bez dima, naprave za simuliranje pušenja, naprave za inhaliranje bez izgaranja duhana, spremnike s aromama.
Use according to Claim 6 or 7, in the treatment and/or prevention of pigmentary disorders. 
Uporaba prema zahtjevu 6, naznačena time da je za liječenje i/ili sprečavanje pigmentacijskih poremećaja.
The pharmaceutical composition of claim 2 in the form of a capsule, tablet, powder, granule, or suspension. 
Farmaceutska kompozicija prema patentnom zahtjevu 2 naznačena time što je u obliku kapsule, tablete, praška, granule ili suspenzije.
Use of a compound of any one of claims 1 to 3 for the manufacture of a medicament for treatment or prevention of a cardiac condition in a subject. 
Uporaba spoja prema patentnom zahtjevu 1, naznačena time što je za proizvodnju lijeka za liječenje ili prevenciju srčanog stanja kod subjekta.
The pharmaceutical composition of any preceding claim, wherein the pharmaceutical composition is suitable for subcutaneous administration. 
Farmaceutska smjesa iz bilo kojeg od prethodnih zahtjeva, naznačena time, što je farmaceutska smjesa pogodna za subkutanu primjenu.
and R2 may be the same or different, and are selected from the group consisting of: 
i R2 mogu biti isti ili različiti, a odabrani su od sljedeće skupine
A combination of a compound as defined in claims 1 to 3 with a second pharmaceutical active component selected from the classes of β2 agonists, M3 antagonists and corticosteroids. 
Kombinacija spoja formule (I) kao što je definirano u patentnim zahtjevima 1 do 7, naznačena time da je s drugom farmaceutski aktivnom komponentom odabranom od sljedećih: klasa 2 agonista, M3 antagnista i koritkosteroidi.
The compound as described in claim 1, which is selected from the group consisting of: pyridin-3-yl 4-(3-phenyl-1H-1,2,4-triazol-5-yl)piperidine-1-carboxylate, 
Spoj, naznačen time, da je odabran iz skupine koju čine: piridin-3-il-4-(3-fenil-1H-1,2,4-triazol-5-il)piperidin-1-karboksilat,
A pharmaceutical composition comprising the compound as described in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljivo pomoćno sredstvo.
Use of the compound as described in claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for treating neuropathic pain. 
Uporaba spoja prema zahtjevu 1 ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje neuropatskih bolova.
Use of the compound as described in claim 1 or a pharmaceutically acceptable salt thereof for the treatment of neuropathic pain. 
Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u postupku liječenja neuropatskih bolova.
A method of manufacture of a microwave or thermally cookable or reheatable food product wherein the product comprises a substrate comprising pieces of poultry, fish, red meat, vegetable, fruit or dairy food; the method comprising the steps of: 
Postupak za proizvodnju prehrambenog proizvoda koji sadrži korake: potpune ili djelomične impregnacije supstrata sa kompozicijom stabilizatora pri čemu supstrat sadrži komade mesa, peradi, ribe, povrća, voća ili mliječnih proizvoda;
A method of manufacture of a food product as claimed in claim 1, wherein the amount of modified starch in the coating composition is 15 to 35% by dry weight. 
Postupak prema patentnom zahtjevu 1, naznačen time što je količina modificiranog škroba u kompoziciji stabilizatora 16 do 35% prema suhoj težini.
A process for the stereoselective preparation of a substantially pure enantiomer of a compound of formula (I), alternatively its enantiomer (I'), wherein P is hydrogen or an amine protecting group, comprising the following steps: 
Postupak stereoselektive pripreme u biti čistog enantiomera spoja formule (I), alternativno njegovog enantiomera (I’), [image] gdje je P vodik ili skupina koja štiti amin, a obuhvaća sljedeće korake:
The process for the stereoselective preparation according to claim 1, wherein P is selected from the group consisting of 9-fluorenylmethyl carbamate (Fmoc), t-butoxycarbonyl (BOC), benzyloxycarbonyl (Cbz), allyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl and benzyl. 
Postupak stereoselektivne pripreme prema zahtjevu 1, gdje se P izabire iz grupe koja obuhvaća 9-fluorenilmetil karbamat (Fmoc), t-butoksikarbonil (BOC), benziloksikarbonil (Cbz), alil, 4-metoksibenzil, 2,4-dimetoksibenzil i benzil.
The process for the stereoselective preparation according to claim 4, wherein the base of the hydrolysis reaction is a hydroxide of an alkali metal. 
Postupak stereoselektivne pripreme prema zahtjevu 4, gdje je lužina za reakciju hidrolize hidroksid alkalnog metala.
Compound Fmoc-(D)-mesityl alanine of opposite configuration to compound of formula (lp). 
Spoj Fmoc-(D)-mesitil alanin suprotne konfiguracije od spoja formule (lp).
A combination of a compound of formula (I) as defined in claims 1 to 7 with a second pharmaceutical active component selected from the classes of β2 agonists, M3 antagonists and corticosteroids. 
Kombinacija spoja formule (I) kao što je definirano u patentnim zahtjevima 1 do 7, naznačena time da je s drugom farmaceutski aktivnom komponentom odabranom od sljedećih: klasa 2 agonista, M3 antagnista i koritkosteroidi.
A compound of formula (I) as defined in claims 1 to 7, for use in the prevention and/or treatment of allergic rhinitis. 
Spoj formule (I) kao što je definiran u patentnim zahtjevima od 1 do 7, naznačena time da se koristi za sprječavanje i/ili liječenje alergijskog rinitisa.
A compound of formula (I) as defined in claims 1 to 7, for use in the prevention and/or treatment of atopic dermatitis. 
Spoj formule (I) kao što je definiran u patentnim zahtjevima od 1 do 7, naznačena time da se koristi za sprječavanje i/ili liječenje atopičnog dermatititsa.
The compound as described in claim 1 or a pharmaceutically acceptable salt thereof for use in a method for treating neuropathic pain. 
Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u postupku liječenja neuropatskih bolova.
Compounds of formula (I) where 
Spojevi formule (I):
or their pharmaceutically acceptable salts, hydrates, or hydrated salts, or the polymorphic crystalline structures of these compounds or their optical isomers, racemates, diastereomers or enantiomers, said derivative being covalently bonded to a cell binding agent through said linker. 
ili njihove farmaceutski prihvatljive soli, hidrati ili hidratirane soli, ili polimorfne kristalne strukture tih spojeva ili njihovi optički izomeri, racemati, dijastereomeri ili enantiomeri, gdje je navedeni spoj kovalentno vezan na sredstvo za vezanje na stanicu preko navedene spojnice.
The plant of claim 2, wherein the sliding punch (46) and the axial through-cavity (33) of the forming matrix (30) are both grooved, such as to give rise to corresponding grooves in a side wall of the beaker-shaped filter (105). 
Postrojenje prema zahtjevu 2, naznačeno time, da su i klizni bušač (46) i aksijalna prolazna šupljina (33) formirajuće matrice (30) užlijebljeni, kako bi podignuli odgovarajuće žljebove u bočnoj stijenci filtera u obliku čašice (105).
The plant of claims 4 and 5, wherein the annular blade (42) is attached to a support body (43), which support body (43) is coupled to the tape ring clamp (35) by means which allow relative movements thereof in an axial direction. 
Postrojenje prema zahtjevima 4 i 5, naznačeno time, da je prstenasto sječivo (42) pričvršćeno na nosivo tijelo (43) koje je povezano na prstenastu spojnicu trake (35) pomoću sredstava koja omogućuju njegove relativne pomake u aksijalnom smjeru.
The plant of claim 6, wherein the support body (43) comprises a truncoconical surface which pushes the tape (13) of filtering material into a truncoconical depression situated at a mouth of the through-cavity (33) of the forming matrix (30). 
Postrojenje prema zahtjevu 6, naznačeno time, da nosivo tijelo (43) obuhvaća krnje stožastu površinu koja gura traku (13) filterskog materijala u krnje stožasto udubljenje smješteno na ulazu prolazne šupljine (33) formirajuće matrice (30).
The plant of claim 9, wherein the welding devices (5, 6) weld at least partially-overlapping portions of the edge of the beaker-shaped filter (105). 
Postrojenje prema zahtjevu 9, naznačeno time, da su prva i druga zavarivačka stanica (5, 6) raspoređene za zavarivanje barem djelomično preklapajućih komada brida filtera u obliku čašice (105).
A pharmaceutical composition comprising at least two peptides wherein the peptides comprise an amino acid selected from the group consisting of SEQ ID NO:1 to SEQ ID NO: 11; provided that the composition comprises at least one peptide comprising SEQ ID NO: 1 or SEQ ID NO:2 or a variant or salt thereof; provided that the peptide is not the full-length human tumour associated polypeptide; and further comprising mannitol and Tween 80®, wherein the ratio by weight of peptides to mannitol to Tween 80® ranges between 1:2:1.5 to 1:8:2.2. 
Farmaceutski sastav prema zahtjevu 1, koji se sastoji od najmanje dva peptida, gdje spomenuti peptidi sadrže slijed aminokiselina odabranih iz skupina koje se sastoje od ID br. baz.: 1 do ID br. baz.: 10, ili ID br. baz.: 12 do ID br. baz.: 23; pod uvjetom da sastav sadrži najmanje jedan peptid koji uključuje ID br. baz.:1, ID br. baz.: 2, ID br. baz.: 12 ili ID br. baz.: 13 ili njihove soli koje dalje uključuju manitol i Tween®80 gdje je omjer prema težini peptida prema manitolu prema Tween® 80 u rasponu uključujući i između 1:2:1.5 do 1:8:2.2.
A compound selected from the group consisting of: 
Spoj izabran iz grupe koju čine: [image]
A process for preparing Compound 10: which process comprises: 
Postupak za pripremu spoja 10: [image] koji sadrži:
reacting Compound 9 with an acid to produce Compound 10 . 
reakciju spoja 9 sa kiselinom da se proizvede spoj 10.
A process for preparing Compound 6: which process comprises preparing Compound 10 by the process according to any one of claims 2 to 10 and converting Compound 10 to Compound 6 . 
Postupak za pripremu spoja 6: [image] koji sadrži pripremu spoja 10 pomoću postupka prema bilo kojem od patentnih zahtjeva 2 do 10 i konverziju spoja 10 u spoj 6.
The process of claim 11, wherein said step of converting Compound 10 to Compound 6 comprises reacting Compound 10 with malonic acid in a second solvent, wherein said second solvent is preferably selected from the group consisting of halogenated solvents, aromatic solvents and nitrogen-containing solvents, particularly from the group consisting of pyridine and toluene. 
Postupak prema patentnom zahtjevu 11, u kojem navedeni korak konverzije spoja 10 u spoj 6 sadrži reakciju spoja 10 sa malonskom kiselinom u drugom otapalu, pri čemu je navedeno drugo otapalo poželjno izabrano iz grupe koju čine halogenizirana otapala, aromatična otapala i otapala koja sadrže dušik, posebno iz grupe koju čine piridin i toluen.
The process of claim 29, further comprising the use of a nitrogen-based catalyst to accelerate the reaction, wherein said nitrogen-based catalyst is selected from the group consisting of piperidine, pyrrolidine, piperazine, pyridine, and triethylamine. 
Postupak prema patentnom zahtjevu 14, koji dalje sadrži upotrebu katalizatora na bazi dušika za ubrzavanje reakcije, pri čemu je navedeni katalizator na bazi dušika izabran iz grupe koju čine piperidin, pirolidin, piperazin, piridin i trietilamin.